N-acetyl-L-cysteine reduces Leishmania amazonensis-induced inflammation in BALB/c mice

• Main Authors: Rosalia Crupi, Enrico Gugliandolo, Rosalba Siracusa, Daniela Impellizzeri, Marika Cordaro, Rosanna Di Paola, Domenico Britti, Salvatore Cuzzocrea
• Format: Article
• Language: English
• Published: BMC 2020-01-01
• Series: BMC Veterinary Research
• Subjects: Leishmaniasis; Inflammation; Mice; Pain
• Online Access: https://doi.org/10.1186/s12917-020-2234-9

Abstract Background Leishmaniasis is a emergent disease characterized by different clinical manifestations in both humans and dogs. Predominant clinical features of cutaneous leishmaniasis are ulcerative painless skin lesions. Several data reported that pain is associated with human and dog leishmaniasis, out with areas of painless ulcerative lesions per se. Actually, current medications used for leishmaniasis management are characterized by several side effects and, in addition, some cases of the disease are refractory to the treatment. On this background it is mandatory the identification of new and safe candidates for designing less toxic and low-cost remedies. Therefore, the search for new leishmanicidal compounds is indispensable. Methods In the present paper we investigated the effect of orally N-acetyl-L-cysteine (NAC) supplementation at dose of 200 mg/Kg for 10 weeks, in subcutaneous Leishmania (L). amazonensis infected BALB/c mice. And evaluating the effect of NAC on inflammatory response such as TNF-α, IL-6, IL-1β levels, and on thermal and mechanical hyperalgesia. Results In the present paper we showed how NAC supplementation affected parameters of oxidative stress (GSH, MDA, SOD), inflammation such as cytokines levels (IL-1β, IL-6, TNFα) and mast cell activation and consequently on induced pain, during leishmaniosis in BALB\c mice. Conclusions The findings of our study provided the scientific data demonstrating that L. amazonensis infection induces inflammation and pain in BALB/c mice that are reversed by administration of NAC.